{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000154","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.003258+00:00","generated_at":"2026-06-11T22:44:43.345363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zentalis Q2 cash $553M; azenosertib ORR 36.8% with RP2D set","bullets":["Cash, equivalents and marketable securities $553.0M as of June 30, 2023; runway into 2026.","Azenosertib monotherapy ORR 36.8% in ovarian cancer/USC; RP2D set at 400 mg QD 5:2.","Phase 1b azenosertib + paclitaxel ORR 50.0% (mPFS 7.4 mo); + carboplatin ORR 35.7% (mPFS 10.4 mo).","Q2 R&D expense $42.7M, G&A $15.7M; one-time Zentera termination charge $45.6M.","Closed $250M public offering (11.03M shares at $22.66) in June; appointed CSO Kimberly Freeman."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000154","json":"https://secwatch.observer/filing/0001725160-23-000154.json","markdown":"https://secwatch.observer/filing/0001725160-23-000154.md","text":"https://secwatch.observer/filing/0001725160-23-000154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/0001725160-23-000154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/zntl-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:44:43.345363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ce4326474ea4a546df7a4dd6fb93d3a61b1ae93","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000154/0001725160-23-000154-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}